Workup for Acromegaly
Begin with serum IGF-1 measurement as the initial screening test, and if elevated or equivocal, confirm the diagnosis with an oral glucose tolerance test (OGTT) demonstrating failure of GH suppression to <1 μg/L, followed by pituitary MRI imaging. 1
Biochemical Diagnosis Algorithm
Step 1: Initial Screening
- Measure serum IGF-1 in any patient with:
Critical pitfall: Do NOT rely on random GH levels for diagnosis—GH secretion is pulsatile and unreliable for diagnostic purposes 1. Random GH may inform prognosis but is not required for diagnosis 2.
Step 2: Confirmatory Testing
If IGF-1 is elevated or equivocal:
- Perform 75g OGTT and measure GH at baseline, 30,60,90, and 120 minutes 1
- Diagnostic criterion: Failure to suppress GH to <1 μg/L (with ultrasensitive assays, the threshold is approximately 0.4 μg/L) 3
- For borderline cases: IGF-1 >1.3 times the upper limit of normal for age confirms diagnosis 2
Important considerations:
- Use age-adjusted and sex-adjusted reference ranges for IGF-1 3
- Confounding factors affecting IGF-1 interpretation: diabetes, liver/renal disease, obesity, pregnancy, estrogen use 3
- Maintain the same validated IGF-1 assay throughout patient management due to assay variability 1
Imaging Studies
Step 3: Pituitary Imaging
Once biochemical diagnosis is confirmed:
- Obtain pituitary MRI with 2mm slices (preferred) or CT if MRI contraindicated 1
- Assess tumor size, location, parasellar extension, and cavernous sinus invasion 1
- If tumor abuts optic chiasm: Perform formal visual field testing 1
Rare scenario: If MRI shows normal pituitary despite confirmed biochemical acromegaly, measure serum GHRH and consider somatostatin receptor scintigraphy (octreoscan) plus thoracic/abdominal imaging to evaluate for ectopic GH or GHRH-secreting tumors 1.
Comorbidity Assessment
Step 4: Systematic Comorbidity Screening
All patients require evaluation for:
Cardiovascular/Metabolic:
- Hypertension screening
- Fasting glucose and HbA1c (consider OGTT if borderline) 4
- Lipid panel (expect hypertriglyceridemia, low HDL) 4
- Echocardiogram for cardiomyopathy/valvular disease 1
Respiratory:
- Sleep study for obstructive and central sleep apnea (present in >50% of patients) 1
Neoplastic:
Endocrine:
- Assess for hypopituitarism (ACTH, TSH, gonadotropins, prolactin) and replace deficits 1
Musculoskeletal:
- Evaluate for arthropathy, carpal tunnel syndrome 1
Metabolic liver disease:
- Screen for hepatic steatosis (present in >60%) 4
Key Clinical Pearls
Diagnostic delay averages 6-10 years 3, emphasizing the need for high clinical suspicion in patients with nonspecific symptoms like sleep apnea, arthralgia, or metabolic disturbances without obvious acral changes.
The Endocrine Society 2014 guidelines 1 remain the authoritative framework, though recent consensus statements 2 have refined GH suppression thresholds with ultrasensitive assays and emphasized that IGF-1 >1.3× upper limit of normal is diagnostic in patients with typical features.
Avoid routine abdominal ultrasound for gallstone screening in asymptomatic patients, even those on somatostatin receptor ligands—only perform if symptomatic 1.
Comorbidities require longitudinal monitoring and aggressive management as they directly impact mortality and quality of life, even after biochemical control is achieved 1.